98%
921
2 minutes
20
Waiting times for medical imaging examinations in Canada are growing as the demand for these tests exceeds current capacity. This document summarizes strategies that may be employed to increase medical imaging patient throughput in an environment of limited resources. This document also advocates for provincial measures to optimize use of resources and national policies that support sustainable radiology services to meet growing demand now and in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/08465371251361082 | DOI Listing |
Background: Actinomyces graevenitzii is a relatively uncommon Actinomyces species, which is an oral species and predominantly recovered from respiratory locations [1,2]. It is a gram-positive anaerobic bacteria or microaerobic filamentation bacteria, which can induce pyogenic and granulomatous inflammation characterized by swelling and concomitant pus, sinus formation, and the formation of yellow sulfur granules. All tissues and organs can be infected; the most common type involves the neck and face (55%), followed by the abdominal and pelvic cavities (20%).
View Article and Find Full Text PDFJ Proteome Res
September 2025
State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Institute of Lifeomics, Beijing 102206, China.
Hepatocellular carcinoma (HCC) constitutes approximately 90% of liver cancers, yet its early detection remains challenging due to the low sensitivity of current diagnostic methods and the difficulty in identifying minimal cancer cells within the body. This study employed a patient-derived xenograft (PDX) mouse model to screen for biomarkers, leveraging its advantage of low background interference compared to human serum exosome studies. Using a novel microextraction technique, exosomes were isolated from just one microliter of serum from HCC PDX mice, followed by proteomic profiling.
View Article and Find Full Text PDFJCI Insight
September 2025
The Arthur and Sonia Labatt Brain Tumor Research Center, The Hospital for Sick Children; Toronto, Canada.
More than a third of patients with glioblastoma experience tumor progression during adjuvant therapy. In this study, we performed a high-throughput drug repurposing screen of FDA-approved agents capable of crossing the blood-brain barrier in order to find agents to counteract acquired or inherent glioma cell resistance to temozolomide-associated cytotoxicity. We identified the cholesterol processing inhibitor, lomitapide, as a potential chemosensitizer in glioblastoma.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Trastuzumab-containing therapy remains a treatment option for patients with HER2-positive gastric cancer (GC). However, primary resistance to trastuzumab is a challenge. Therefore, it is essential to identify biomarkers for predicting the efficacy of trastuzumab-based treatment.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
The Unit of Pathogenic Fungal Infection & Host Immunity, CAS Key Laboratory of Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
Rationale: Cytomegalovirus (CMV) is a DNA virus from the herpesvirus family that is widespread among humans. Very low birth weight infants (VLBWI) are particularly susceptible to postnatal CMV infection due to their compromised immune systems. The clinical manifestations of postnatal CMV infection are often nonspecific, which complicates early detection and may lead to multi-organ dysfunction and long-term sequelae.
View Article and Find Full Text PDF